Disseminated intravascular coagulation in trauma injuries.

abstract：:Patients with unprovoked venous thromboembolism (VTE) may harbor occult cancer. Whether an extensive diagnostic work-up for cancer has additional value over a more limited screening for detection of underlying malignancy in these patients is controversial. We performed a randomized multicenter trial to assess if in pa...

journal_title：Seminars in thrombosis and hemostasis

authors： Prandoni P,Bernardi E,Valle FD,Visonà A,Tropeano PF,Bova C,Bucherini E,Islam MS,Piccioli A

更新日期：2016-11-01 00:00:00

abstract：:The proinflammatory cytokine storm associated with coronavirus disease 2019 (COVID-19) negatively affects the hematological system, leading to coagulation activation and endothelial dysfunction and thereby increasing the risk of venous and arterial thrombosis. Coagulopathy has been reported as associated with mortalit...

journal_title：Seminars in thrombosis and hemostasis

authors： Zadow EK,Wundersitz DWT,Hughes DL,Adams MJ,Kingsley MIC,Blacklock HA,Wu SSX,Benson AC,Dutheil F,Gordon BA

更新日期：2020-10-01 00:00:00

abstract：:Thrombocytosis is frequently (10 to 57%) observed in cancer patients. Although the mechanisms underlying thrombocytosis are not yet fully elucidated, tumor-derived factors with thrombopoietin-like activity, growth factors, platelet-derived microparticles, and factors released from bone marrow endothelial cells as well...

journal_title：Seminars in thrombosis and hemostasis

authors： Sierko E,Wojtukiewicz MZ

更新日期：2007-10-01 00:00:00

abstract：:Several studies have suggested that patients with non-O blood group have an increased risk of both venous and arterial thromboembolic events. On the contrary, the role of ABO blood group on the risk of bleeding complications remains unclear. Thus, we performed a meta-analysis of the literature with the aim of assessin...

journal_title：Seminars in thrombosis and hemostasis

authors： Dentali F,Sironi AP,Ageno W,Bonfanti C,Crestani S,Frattini F,Steidl L,Franchini M

更新日期：2013-02-01 00:00:00

abstract：:Morbidity and mortality for cardiovascular disease are likely to be lower in patients with hemophilia than in the general male population. However, their clinical impact is increasing in parallel with the increase of life expectancy due to modern safe replacement treatments and the improvement of comprehensive care of...

journal_title：Seminars in thrombosis and hemostasis

authors： Coppola A,Tagliaferri A,Franchini M

更新日期：2010-02-01 00:00:00

abstract：:Severe factor XI (FXI) deficiency is an injury-related bleeding disorder common in Ashkenazi Jews and rare worldwide. In the past two decades, more than 180 mutations in the FXI gene have been reported in patients with FXI deficiency, five of which show a founder effect (Cys38Arg, Gln88Stop, Cys128Stop, Glu117stop, an...

journal_title：Seminars in thrombosis and hemostasis

authors： Duga S,Salomon O

更新日期：2009-06-01 00:00:00

abstract：:Oral anticoagulants (OAs) are the drugs of choice for the prevention of recurrence and death in patients with venous thromboembolism (VTE). Oral anticoagulant treatment (OAT) aims to retard blood coagulation to obtain maximum protection against thromboembolic events with the lowest risk of bleeding. The intensity of O...

journal_title：Seminars in thrombosis and hemostasis

authors： Pengo V

更新日期：2006-11-01 00:00:00

abstract：:We present three clinical cases that illustrate some of the key features of the diagnosis and management of immune-mediated heparin-induced thrombocytopenia (HIT). The importance of having a high clinical suspicion for HIT in the appropriate clinical setting is emphasized. Early therapeutic decisions should be based o...

journal_title：Seminars in thrombosis and hemostasis

authors： Smith KJ,Call JT,Sane DC

更新日期：2004-06-01 00:00:00

abstract：:Patients receiving heparin are at risk of developing heparin-induced thrombocytopenia (HIT). Whereas in HIT I only reversible mild thrombocytopenia occurs within the first days of heparin treatment, HIT II may lead to potentially life-threatening thromboembolic events. Pediatric patients suffering from HIT II have bee...

journal_title：Seminars in thrombosis and hemostasis

authors： Severin T,Zieger B,Sutor AH

更新日期：2002-10-01 00:00:00

abstract：:Antithrombin activity should probably be determined in persons with early onset of recurrent thrombosis, especially if a family history is present. The initial screening test should be a heparin cofactor assay optimized to reduce the contribution of heparin cofactor II. If the heparin cofactor assay is low, an antigen...

journal_title：Seminars in thrombosis and hemostasis

authors： Tollefsen DM

更新日期：1990-04-01 00:00:00

abstract：:Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are altepl...

journal_title：Seminars in thrombosis and hemostasis

authors： Campbell J,Hilleman D

更新日期：2010-07-01 00:00:00

abstract：:Current guidelines for venous thromboembolism (VTE) primary prophylaxis are based on randomized clinical trials that exclude subjects at a potentially high bleeding risk. Thus no specific recommendation/algorithm for pharmacological prophylaxis in patients with thrombocytopenia and/or platelet dysfunction is available...

journal_title：Seminars in thrombosis and hemostasis

authors： Tufano A,Guida A,Di Minno MN,Prisco D,Cerbone AM,Di Minno G

更新日期：2011-04-01 00:00:00

abstract：:In addition to the criteria of the Polycythemia Vera Study Group, positive markers for essential thrombocythemia (ET) include spontaneous BFU-E, splenomegaly, and megakaryocyte morphology in bone marrow smears and biopsy material. The hematologic features of 11 reported cases of ET in childhood showed platelet counts ...

journal_title：Seminars in thrombosis and hemostasis

authors： Michiels JJ,Van Genderen PJ

更新日期：1997-01-01 00:00:00

abstract：:Eradication of factor VIII (FVIII) specific neutralizing antibodies (also known as inhibitors) by the traditional method of immune tolerance induction (ITI) is costly and unsuccessful in one out of three patients. Furthermore, effective inhibitor prevention strategies are presently lacking. An overview is given in thi...

journal_title：Seminars in thrombosis and hemostasis

authors： Hassan S,Fijnvandraat K,van der Bom JG,Gouw SC

更新日期：2018-09-01 00:00:00

abstract：:It has been well known for many years that the ABO blood group has a major influence on hemostasis, through its influence on von Willebrand factor and, consequently, factor VIII plasma levels. Although the relationship between non-O blood type and the risk of venous thromboembolism is nowadays also well established, t...

journal_title：Seminars in thrombosis and hemostasis

authors： Dentali F,Sironi AP,Ageno W,Crestani S,Franchini M

更新日期：2014-02-01 00:00:00

abstract：INTRODUCTION:The aim of this study was to evaluate the genetic variability of selected single nucleotide polymorphisms (SNPs) within GAS6 and PEAR1 genes and explore the association between selected SNPs and risk for fetal loss in women with sticky platelet syndrome (SPS). MATERIALS AND METHODS:We examined 23 female p...

journal_title：Seminars in thrombosis and hemostasis

authors： Sokol J,Biringer K,Skerenova M,Stasko J,Kubisz P,Danko J

更新日期：2015-04-01 00:00:00

abstract：:The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

journal_title：Seminars in thrombosis and hemostasis

authors： Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

更新日期：1997-01-01 00:00:00

abstract：:Most plasma proteins are present in both normal and atherosclerotic intima, and their concentrations in intimal interstitial fluid are directly related to plasma concentration and molecular size. All intimal samples also contain soluble fibrin-fibrinogen-related antigens, consisting of variable mixtures of fibrinogen ...

journal_title：Seminars in thrombosis and hemostasis

authors： Smith EB,Crosbie L,Carey S

更新日期：1996-01-01 00:00:00

abstract：:Platelets have classically been considered crucial effector cells in hemostasis, but now are increasingly recognized as players during inflammatory responses in innate and adaptive immunity. Platelets can recognize and kill invading pathogens, and, upon stimulation, also release a wide array of mediators that modify i...

journal_title：Seminars in thrombosis and hemostasis

authors： Kim SJ,Davis RP,Jenne CN

更新日期：2018-03-01 00:00:00

abstract：:Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissol...

journal_title：Seminars in thrombosis and hemostasis

authors： Yamamoto K,Takeshita K,Saito H

更新日期：2014-09-01 00:00:00

abstract：:Endothelial phenotypic heterogeneity plays an important role in the susceptibility of the cardiovascular system to disease. Arteries and heart valves are susceptible to chronic inflammatory disease in regions of blood flow disturbance that implicates hemodynamic forces and transport characteristics as prominent influe...

journal_title：Seminars in thrombosis and hemostasis

authors： Davies PF,Civelek M,Fang Y,Guerraty MA,Passerini AG

更新日期：2010-04-01 00:00:00

abstract：:Polycystic ovarian syndrome (PCOS) affects 12 to 19% of women and has reproductive and metabolic features (endothelial dysfunction, increased diabetes, and cardiovascular risk factors). It also appears to have altered coagulation and fibrinolysis with a prothrombotic state with epidemiological evidence of increased ve...

journal_title：Seminars in thrombosis and hemostasis

authors： Burchall GF,Piva TJ,Linden MD,Gibson-Helm ME,Ranasinha S,Teede HJ

更新日期：2016-02-01 00:00:00

abstract：:Persons with hematologic malignancies bleed for a variety of reasons, including alterations in platelet function and numbers, clotting factor deficiencies, circulating anticoagulants, and defects in vascular integrity. The management of bleeding begins with a full characterization of the hemostatic defect. Vitamin K d...

journal_title：Seminars in thrombosis and hemostasis

authors： Green D

更新日期：2007-06-01 00:00:00

abstract：:In order to determine whether maternal smoking before or during pregnancy, or both, is associated with a reduced risk for preeclampsia in Japanese subjects, we conducted a case-control study that took other risk factors for preeclampsia into consideration. Seventy-one preeclampsia patients were matched with 142 contro...

journal_title：Seminars in thrombosis and hemostasis

authors： Kobashi G,Ohta K,Hata A,Shido K,Yamada H,Fujimoto S,Kondo K

更新日期：2002-12-01 00:00:00

abstract：:Of all the coagulation factor deficiencies, only deficiency of factor XIII (FXIII) and fibrinogen are associated with pregnancy loss. FXIII deficiency and a complete or partial deficiency of fibrinogen are associated with bleeding since childhood, impaired wound repair, and recurrent spontaneous abortions. Both FXIII ...

journal_title：Seminars in thrombosis and hemostasis

authors： Inbal A,Muszbek L

更新日期：2003-04-01 00:00:00

abstract：:Coagulation management requires the balancing of different components that contribute to clot formation. These components include the interactions between platelets, procoagulant, anticoagulant, and fibrinolytic factors. The cause of bleeding or thrombotic events is often multifactorial; however, the tests clinicians ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wegner J,Popovsky MA

更新日期：2010-10-01 00:00:00

abstract：:Statins are approved by the Food and Drug Administration (FDA) for the treatment of hypercholesterolemia and have shown remarkable activity in preventing cardiovascular morbidity and mortality. The versatility of statins is increasingly being appreciated, however, and lowering cholesterol is only one attribute among m...

journal_title：Seminars in thrombosis and hemostasis

authors： Splichal JE,Stamm JA,Ornstein DL

更新日期：2003-06-01 00:00:00

abstract：:von Willebrand disease (VWD) was first described nearly a century ago in 1924 by Erik Adolf von Willebrand. Diagnostic testing at the time was very limited and it was not until the mid to late 1900s that more tests became available to assist with the diagnosis and classification of VWD. Two of these tests are based on...

journal_title：Seminars in thrombosis and hemostasis

authors： Just S

更新日期：2017-02-01 00:00:00

abstract：:We experienced 23 cases of venous thrombosis after gynecological surgery for the past 12 years at Tokyo Women's Medical University Hospital, representing 0.345 % of all patients. Eighteen of the 23 cases had deep venous thrombosis (DVT) including five cases followed by pulmonary embolism (PE), and five cases had PE wi...

journal_title：Seminars in thrombosis and hemostasis

authors： Adachi T,Nakabayashi M,Takeda Y

更新日期：1998-01-01 00:00:00

abstract：:Current concepts of the cause, pathophysiologic mechanisms, diagnosis, and management of acute and chronic DIC have been discussed. Considerable attention has been devoted to interrelationships that have remained confusing. Only by clearly understanding these pathophysiologic interrelationships can the clinician and l...

journal_title：Seminars in thrombosis and hemostasis

authors： Bick RL

更新日期：1988-10-01 00:00:00